Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Mahmoud Kandeel. (2023) An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery. Expert Opinion on Drug Discovery 18:4, pages 385-400.
Read now
Read now
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian & Yongping Zhang. (2022) Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China. Infection and Drug Resistance 15, pages 6463-6470.
Read now
Read now
Emre Durcan, Senol Turan, Basak Ecem Bircan, Selver Yaylamaz, Oznur Demirel, Ahmet Numan Demir, Cem Sulu, Zehra Kara, Serdar Sahin, Sabriye Sibel Taze, Hande Mefkure Ozkaya & Pinar Kadioglu. (2022) TransCOVID: Does Gender-Affirming Hormone Therapy Play a Role in Contracting COVID-19?. Journal of Sex & Marital Therapy 48:4, pages 415-426.
Read now
Read now
Shivani Krishna Kapuganti, Aparna Bhardwaj, Prateek Kumar, Taniya Bhardwaj, Namyashree Nayak, Vladimir N. Uversky & Rajanish Giri. (2022) Role of structural disorder in the multi-functionality of flavivirus proteins. Expert Review of Proteomics 19:3, pages 183-196.
Read now
Read now
Abdul Majeed, Iltaf Hussain, Imran Imran, Muhammad Usman Saleem, Hamid Saeed, Muhammad Asad Abrar, Muhammad Islam, Furqan K Hashmi, Muqarrab Akbar, Basit Ramzan, Muhammad Omer Chaudhry, Waseem Ashraf & Muhammad F Rasool. (2021) Assessing Barriers Faced by Surgeons While Providing Surgical Care During the COVID-19 Pandemic in Pakistan: An Online Cross-Sectional Study. Journal of Multidisciplinary Healthcare 14, pages 665-672.
Read now
Read now
Miao Miao, Xixi Jing, Erik De Clercq & Guangdi Li. (2020) Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Design, Development and Therapy 14, pages 2759-2774.
Read now
Read now
Foster Kofi Ayittey, Bablu Kumar Dhar, Gideon Anani & Nyasha Bennita Chiwero. (2020) Gendered burdens and impacts of SARS-CoV-2: a review. Health Care for Women International 41:11-12, pages 1210-1225.
Read now
Read now
Noura H Abd Ellah, Sheryhan F Gad, Khalid Muhammad, Gaber E Batiha & Helal F Hetta. (2020) Nanomedicine as A Promising Approach For Diagnosis, Treatment and Prophylaxis Against COVID-19. Nanomedicine 15:21, pages 2085-2102.
Read now
Read now
Articles from other publishers (44)
Xu Chen, Shilei Dong, Yuanfang Shi, Zengguang Wu, Xue Wu, Xiaoyan Zeng, Xinggui Yang, Qi Zhao, Zhenghua Xiao & Qingxue Zhou. (2024) Biosensor‐based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus. Journal of Medical Virology 96:3.
Crossref
Crossref
Yuanfang Shi, Qingxue Zhou, Shilei Dong, Qi Zhao, Xue Wu, Peng Yang, Xiaoyan Zeng, Xinggui Yang, Yan Tan, Xinhua Luo, Zhenghua Xiao & Xu Chen. (2024) Rapid, visual, label-based biosensor platform for identification of hepatitis C virus in clinical applications. BMC Microbiology 24:1.
Crossref
Crossref
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang & Chaoshuang Lin. (2024) Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. BMC Gastroenterology 24:1.
Crossref
Crossref
Yuanyuan Jia, Xiu Zou, Wei Yue, Jin Liu, Ming Yue, Yang Liu, Li Liu, Peng Huang, Yue Feng & Xueshan Xia. (2023) The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan, China, between 2008–2018. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Crossref
Saja Mohammed Mohsen & Ghanim Hussein Majeed. (2023) Knowledge and awareness of chronic hepatitis C and liver fibrosis among health care personnel and other domains in Iraq. Bionatura 8:1, pages 1-6.
Crossref
Crossref
Shoukat Ali, Basit Ali, Bakht B Khan, Manzar Khan, Sohail Ali, Asif Iqbal, Tamreez Khan, Shafqat Ullah, Mujeeb Ur Rahman & Maryam Gul. (2023) Sero-prevalence of hepatitis-c virus among blood donors in northern Pakistan. MOJ Public Health 12:1, pages 37-41.
Crossref
Crossref
Bishguurmaa Renchindorj, Bo Kyeung Jung & Joowon Park. (2022) Analysis of Hepatitis C Virus Genotypes and RNA Quantitative Values in Cheonan, Republic of Korea from 2007 to 2016. Microbiology and Biotechnology Letters 50:3, pages 422-429.
Crossref
Crossref
Ruijun Su, Li DongYongxiang WangRenna SaYafei Wang. (2022) Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia. Medicine 101:28, pages e29545.
Crossref
Crossref
Jia Yang, Hui-Xin Liu, Ying-Ying Su, Zhi-Sheng Liang & Hui-Ying Rao. (2022) Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. World Journal of Clinical Cases 10:14, pages 4480-4493.
Crossref
Crossref
Ekta Gupta, Jasmine Samal, Amit Pandey, Gaurav Singh, Hajra A. S. Gupta, Reshu Agarwal & Manoj Kumar Sharma. (2022) Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA. Viruses 14:5, pages 944.
Crossref
Crossref
Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin, Tao Han, Yuemin Nan & Liaoyun Zhang. (2022) Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022, pages 1-11.
Crossref
Crossref
Ling-Xiao Qu, Yang Shi, Kai-Yun Chen, Yi-Han Lu & Hong Ren. (2021) The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. BMC Infectious Diseases 21:1.
Crossref
Crossref
Xue MeiHongzhou Lu. (2021) Prevalence, diagnosis, and treatment of hepatitis C in Mainland China. Global Health & Medicine 3:5, pages 270-275.
Crossref
Crossref
Yuanyuan Jia, Wei Yue, Qinghua Gao, Rui Tao, Yaxiang Zhang, Xiaoyang Fu, Yang Liu, Li Liu, Yue Feng & Xueshan Xia. (2021) Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiology Spectrum 9:1.
Crossref
Crossref
Fei Kong, Xiaoyu Wen, Xiaofeng Wen, Xiaozhong Wang, Guicheng Wu, Shide Lin, Li Wang, Huichun Xing, Xuebing Yan, Sujun Zheng, Qin Ning, Zheng Wang, Liaoyun Zhang, Jianmei Lin, Zhaowei Tong, Chengyu Huang, Minghua Su, Lixin Tong, Jidong Jia, Yongning Xin, Qingjing Zhu, Jing Wang, Li Chen, Xiaowen Li, Xuegang Wu, Duan Niu, Quan Liu, Wei Wei, Yuexin Zhang, Guangming Li & Junqi Niu. (2021) Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial. Journal of Gastroenterology and Hepatology 36:9, pages 2375-2382.
Crossref
Crossref
Velia Chiara Di Maio, Silvia Barbaliscia, Elisabetta Teti, Gianluca Fiorentino, Martina Milana, Stefania Paolucci, Teresa Pollicino, Giulia Morsica, Mario Starace, Bianca Bruzzone, William Gennari, Valeria Micheli, Katia Yu La Rosa, Luca Foroghi, Vincenza Calvaruso, Ilaria Lenci, Ennio Polilli, Sergio Babudieri, Alessio Aghemo, Giovanni Raimondo, Loredana Sarmati, Nicola Coppola, Caterina Pasquazzi, Fausto Baldanti, Giustino Parruti, Carlo Federico Perno, Mario Angelico, Antonio Craxì, Massimo Andreoni & Francesca Ceccherini‐Silberstein. (2021) Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C. Liver International 41:8, pages 1802-1814.
Crossref
Crossref
Hung-Da Tung, Pei-Lun Lee, Jyh-Jou Chen, Hsing-Tao Kuo, Ming-Jen Sheu, Chun-Ta Cheng, Tang-Wei Chuang, Hsu-Ju Kao, Yu-Hsun Wu, Mai-Gio Pang, Cheng-Heng Lin, Chia-Yi Hou, Hsin-Hua Tsai, Li-Ching Wu & Chuan Lee. (2021) Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution. Viruses 13:7, pages 1316.
Crossref
Crossref
Shufang Pan, Kai Feng, Ping Huang, Yingfu Zeng, Liu Ke, Xiaodong YangJing Liu & Chaoshuang Lin. (2021) Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine 100:24, pages e26312.
Crossref
Crossref
Liyu Chen, Lingyao Du, Shuang Kang, Fanghua Ma, Changmin Li, Min He, Lang Bai & Hong Tang. (2021) Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Scientific Reports 11:1.
Crossref
Crossref
Bing Chen, Zhong‐Hui Ma, Bing Xu, Hao Chang, Xiao‐Xia He, Li‐Jian Pei, Ya‐Nan Ren & Wen‐Ge Xing. (2021) Evaluation of seven rapid diagnostic tests for detection of hepatitis C virus antibodies in China. Journal of Viral Hepatitis 28:4, pages 657-663.
Crossref
Crossref
Xiaoqing Liu & Peng Hu. (2021) Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. Journal of Clinical and Translational Hepatology 000:000, pages 000-000.
Crossref
Crossref
Zuqiang Fu, Weihua Cai, Jianguo Shao, Hong Xue, Zhijun Ge, Haozhi Fan, Chen Dong, Chunhui Wang, Jinwei Zhang, Chao Shen, Yun Zhang, Peng Huang & Ming Yue. (2021) Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population. Frontiers in Genetics 12.
Crossref
Crossref
Fanpu Ji, Jie Li, Li Liu, Jing Liang, Xiaozhong Wang, Junping Liu, Dachuan Cai, Rui Huang, Jiajie Zhang, Qi Wang, Yuemin Nan, Junyi Li, Qing Ye, Mingyuan Zhang, Qiang Xu, Feng Guo, Changqing Zhao, Lingdi Liu, Caini He, Yu Li, Wenjun Wang, Leslie Y Kam, Sally Tran, Mayumi Maeda, Akiko Mizuta, Zongfang Li, Shuangsuo Dang, Wanhua Ren, Qiang Zhu, Ramsey Cheung, Junqi Niu, Wen Xie, Hongying Pan, Hong Ren, Chao Wu, Jia Shang, Fengmei Wang & Mindie H Nguyen. (2020) High hepatitis C virus cure rates with approved interferon‐free direct‐acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. Journal of Gastroenterology and Hepatology 36:3, pages 767-774.
Crossref
Crossref
Tyng-Yuan Jang, Po-Cheng Liang, Ta-Wei Liu, Yu-Ju Wei, Ming-Lun Yeh, Cheng-Ting Hsu, Po-Yao Hsu, Yi-Hung Lin, Meng-Hsuan Hsieh, Ching-I Huang, Chung-Feng Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu & Wan-Long Chuang. (2021) Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. Journal of the Chinese Medical Association 84:3, pages 255-260.
Crossref
Crossref
Cas J Isfordink, Thijs J W van de Laar, Sjoerd P H Rebers, Els Wessels, Richard Molenkamp, Marjolein Knoester, Bert C Baak, Cees van Nieuwkoop, Bart van Hoek, Sylvia M Brakenhoff, Hans Blokzijl, Joop E Arends, Marc van der Valk, Janke Schinkel, Sophie Willemse, Robin Erken, Marije Bomers, Dewkoemar Ramsoekh, U M C Amsterdam, Rob de Knegt, Rob de Man, Bart Rijnders, M C Erasmus, Hanneke van Soest, M C Haaglanden, Ger Koek, Dirk Posthouwer, Ozgür Koc, U M C Maastricht, David Burger, Marleen van Dijk, Joost Drenth, Daan von den Hoff, U M C Radboud, Johannes Brouwer, Reinier de Graaf Gasthuis, Greet Boland, Karel van Erpecum & U M C Utrecht. (2021) Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infectious Diseases 8:2.
Crossref
Crossref
Rongkuan Li, Ying Xie, Wenzhi Liu & Yu Ma. (2021) Hepatitis C virus genotype and subtype distribution among ethnic minorities in Liaoning Province of China. Medicine 100:2, pages e24137.
Crossref
Crossref
Zhichao Ma, Yi Sun, Pengqiang Du & Xingang Li. (2020) Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin‐induced anaemia and outcome in hepatitis C virus‐infected patients: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 45:6, pages 1218-1227.
Crossref
Crossref
Yong-yu Mei, You-ming Chen, Yuan-kai Wu, Xiao-hong Zhang & Wen-xiong Xu. (2020) Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Canadian Journal of Gastroenterology and Hepatology 2020, pages 1-8.
Crossref
Crossref
Huiying Rao, Xingxiang Yang, Youwen Tan, Qin Ning, Daokun Yang, Jiefei Wang, Yongfeng Yang, Sujun Zheng, Dongliang Yang, Jinlin Hou, Qing Xie, Caiyan Zhao, Lunli Zhang, Xiaorong Mao, Tong Sun, Lang Bai, Fuchun Zhang, Jinglan Jin, Yingren Zhao, Maorong Wang, Wen Xie, Yingjie Ma, Jun Quan, Xuebing Yan, Ping An, Feng Lin, Jidong Jia, Xiaoxuan Hu, Zuojiong Gong, Jie Wu, Yongping Chen, Zhansheng Jia, Minghua Lin, Guiqiang Wang, Yueyong Zhu, Yingjun Zhang, Hongming Xie, Lin Luo, Qingyun Ren, Rui Huang & Lai Wei. (2020) Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. Journal of Clinical and Translational Hepatology 8:4, pages 1-7.
Crossref
Crossref
Yusheng Jie, Chaoshuang Lin, Jing Yuan, Zhixin Zhao, Yujuan Guan, Yuanping Zhou, Xiaohui Zhou, Bihui Zhong, Yinong Ye, Lihua Zhang, Ling Tao, Jianping Li, Xiaohong Zhang & Yutian Chong. (2020) Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. Liver Research 4:3, pages 153-158.
Crossref
Crossref
Lai Wei, Guiqiang Wang, Negar N Alami, Wen Xie, Jeong Heo, Qing Xie, Mingxiang Zhang, Yoon Jun Kim, Seng Gee Lim, Linda M Fredrick, Wenjing Lu, Wei Liu, Hari V Kalluri, Preethi Krishnan, Rakesh Tripathi, Niloufar Mobashery, Margaret Burroughs, Armen Asatryan, Jidong Jia & Jinlin Hou. (2020) Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). The Lancet Gastroenterology & Hepatology 5:9, pages 839-849.
Crossref
Crossref
Huan Xia, Chengzhen Lu, Yin Wang, Silvere D. Zaongo, Yue Hu, Yue Wu, Zhongfang Yan & Ping Ma. (2020) Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Frontiers in Pharmacology 11.
Crossref
Crossref
Xi Ran, HuaiYi Xie & Wei Li. (2020) Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis. Hepatitis Monthly 20:1.
Crossref
Crossref
Nan Wu, Hui-Ying Rao, Wei-Bo Yang, Zhi-Liang Gao, Rui-Feng Yang, Ran Fei, Ying-Hui Gao, Qian Jin & Lai Wei. (2020) Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chinese Medical Journal 133:3, pages 253-261.
Crossref
Crossref
Hiroki Ikeda, Tsunamasa Watanabe, Masanori Atsukawa, Hidenori Toyoda, Koichi Takaguchi, Makoto Nakamuta, Nobuyuki Matsumoto, Chiaki Okuse, Toshifumi Tada, Akemi Tsutsui, Naoki Yamashita, Chisa Kondo, Korenobu Hayama, Keizo Kato, Norio Itokawa, Taeang Arai, Noritomo Shimada, Toru Asano, Haruki Uojima, Chikara Ogawa, Shigeru Mikami, Tadashi Ikegami, Shinya Fukunishi, Akira Asai, Etsuko Iio, Akihito Tsubota, Atsushi Hiraoka, Akito Nozaki, Hironao Okubo, Yoshihiko Tachi, Akio Moriya, Tsunekazu Oikawa, Yoshihiro Matsumoto, Shuichi Tsuruoka, Joji Tani, Kan Kikuchi, Katsuhiko Iwakiri, Yasuhito Tanaka & Takashi Kumada. (2019) Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan. Journal of Viral Hepatitis 26:11, pages 1266-1275.
Crossref
Crossref
Ittipat Meewan, Xingquan Zhang, Suchismita Roy, Carlo Ballatore, Anthony J. O’Donoghue, Robert T. Schooley & Ruben Abagyan. (2019) Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega 4:16, pages 16999-17008.
Crossref
Crossref
Rui Huang, Huiying Rao, Qing Xie, Zhiliang Gao, Wu Li, Deyuan Jiang, Hongmei Mo, Benedetta Massetto, Luisa M. Stamm, Diana M. Brainard & Lai Wei. (2019) Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. Journal of Medical Virology 91:7, pages 1313-1318.
Crossref
Crossref
Jie Lu, Yupeng Feng, Lichang Chen, Zhengyu Zeng, Xianliang Liu, Wei Cai, Hui Wang, Xiaolei Guo, Huijuan Zhou, Wanyin Tao & Qing Xie. (2019) Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Frontiers in Microbiology 10.
Crossref
Crossref
Dong‐Bo Wu, Wei Jiang, Yong‐Hong Wang, Bin Chen, Meng‐Lan Wang, Ya‐Chao Tao, En‐Qiang Chen & Hong Tang. (2018) Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real‐world experience of a retrospective study. Journal of Viral Hepatitis 26:3, pages 316-322.
Crossref
Crossref
Lai Wei, Seng Gee Lim, Qing Xie, Kính Nguyen Văn, Teerha Piratvisuth, Yan Huang, Shanming Wu, Ming Xu, Hong Tang, Jun Cheng, Hung Le Manh, Yanhang Gao, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Xiaguang Dou, Satawat Thongsawat, Yuemin Nan, Chee Kiat Tan, Qin Ning, Hoi Poh Tee, Yimin Mao, Luisa M Stamm, Sophia Lu, Hadas Dvory-Sobol, Hongmei Mo, Diana M Brainard, Yong-Feng Yang, Long Dao, Gui-Qiang Wang, Tawesak Tanwandee, Peng Hu, Pisit Tangkijvanich, Lunli Zhang, Zhi Liang Gao, Feng Lin, Thi Tuyet Phuong Le, Jia Shang, Guozhong Gong, Jun Li, Minghua Su, Zhongping Duan, Rosmawati Mohamed, Jin Lin Hou & Jidong Jia. (2019) Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology 4:2, pages 127-134.
Crossref
Crossref
R Handajani, C D K Wungu, I Humairah, G I Prabowo, U Cholili, M Amin, P B Setiawan & Soetjipto. (2019) Detection Of Hepatitis C Virus (Hcv) Infection And Its Genotype In Patients At Hepatology Outpatient Clinic, Dr Soetomo General Hospital, Surabaya.. IOP Conference Series: Earth and Environmental Science 217, pages 012051.
Crossref
Crossref
Xinyu Wu, Feng Zang, Mei Liu, Lingyun Zhuo, Jingjing Wu, Xueshan Xia, Yue Feng, Rongbin Yu, Peng Huang & Sheng Yang. (2019) Genetic variants in RIG-I-like receptor influences HCV clearance in Chinese Han population. Epidemiology and Infection 147.
Crossref
Crossref
Jing Lu, Li Zhang, Xiaoqin Xu, Yuanfang Chen, Ying Zhou, Zhi Zhang, Gengfeng Fu & Guohong Chen. (2019) Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug and Alcohol Dependence 194, pages 101-106.
Crossref
Crossref
Mingxiao Chen, Fuxiang Zheng, Guosheng Yuan, Xiaobing Duan, Liang Rong, Junwei Liu, Shengjun Feng, Ziting Wang, Min Wang, Yetong Feng, Qing Zhou, Jinqian Li, Kai Deng, Chunna Li, Jinyu Xia, Guirong Rao, Yuanping Zhou, Yongshui Fu & Yi-Ping Li. (2018) Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Frontiers in Microbiology 9.
Crossref
Crossref